Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 24

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Systemic scleroderma+2

Recruiting

Study on the Safety of MB-CART19.1 for Patients with Active Systemic Lupus Erythematosus, Systemic Sclerosis, or Dermatomyositis/Polymyositis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
  • Sponsor:Miltenyi Biomedicine GmbH

Colorectal cancer metastatic

Recruiting

Study of Hyperthermic Intraperitoneal Chemotherapy with Irinotecan and Fluorouracil in Patients with Colorectal Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Uppsala University

Colorectal cancer metastatic

Recruiting

Study on Bevacizumab-Based Chemotherapy for Patients with Unresectable Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Pancreatic carcinoma

Recruiting

Study on the Effectiveness of [18F]FAPI-74 PET/CT for Detecting Lymph Node Spread in Patients with Pancreatic Cancer

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:Turku University Hospital

Colon cancer

Recruiting

Study of 18F-FAPI-74 PET/CT Imaging for Detection of Lymph Node Metastases in Patients with Colon Cancer

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:Turku University Hospital

Cystic fibrosis

Recruiting

Study on the Safety and Effects of SPL84 for Patients with Cystic Fibrosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Splisense Ltd.

Crohn's disease

Recruiting

Study Comparing Azathioprine and Methotrexate with Adalimumab for Patients with Crohn's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Neuroendocrine tumour+6

Recruiting

Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dotatate
  • Sponsor:Region Hovedstaden

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab, Budesonide, and Prednisone for Children with Moderate to Severe Crohn's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Budesonide
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study on Using Fluorescein Sodium to Identify Inflammation in Crohn's Disease Patients During Ileal Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorescein Sodium
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Short-bowel syndrome

Recruiting

Study on Crofelemer for Adults with Short Bowel Syndrome and Intestinal Failure Without Colon in Continuity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Crofelemer
  • Sponsor:Napo Therapeutics S.p.A.

Uveitis+1

Recruiting

Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.